Mesh.i
Exploration
Accueil
Racine
Exploration
Accueil
Racine

Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « Mesh.i » - entrée « Hepatitis B »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Hepatitis A Virus Cellular Receptor 2 < Hepatitis B < Hepatitis B Antibodies  Facettes :

List of bibliographic references indexed by Hepatitis B

Number of relevant bibliographic references: 8.
Ident.Authors (with country if any)Title
000A29 (2019) G. Carlino [Italie] ; M. Fornaro ; L. Santo ; R. Bucci ; A. Semeraro ; L. Quarta ; F. D'Onofrio ; A. Marsico ; C. Zuccaro ; P C Falappone ; D. Mazzotta ; F P Cantatore ; M. Muratore ; F. IannoneOccult HBV infection may negatively impact on drug survival in patients with rheumatoid arthritis on treatment with a first biologic drug. An appraisal from the Biologic Apulian Registry (BIOPURE).
000B83 (2019) Toshiyuki Watanabe [Japon] ; Jun Fukae [Japon] ; Shinji Fukaya [Japon] ; Norifumi Sawamukai [Japon] ; Masato Isobe [Japon] ; Megumi Matsuhashi [Japon] ; Masato Shimizu [Japon] ; Kazumasa Akikawa [Japon] ; Kazuhide Tanimura [Japon] ; Tatsuya Atsumi [Japon] ; Takao Koike [Japon]Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
001212 (2018) Sung Soo Ahn [Corée du Sud] ; Seung Min Jung [Corée du Sud] ; Jason Jungsik Song [Corée du Sud] ; Yong Beom Park [Corée du Sud] ; Jun Yong Park [Corée du Sud] ; Sang Won Lee [Corée du Sud]Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience.
001D36 (2016) Jun Nakamura [Japon] ; Takao Nagashima [Japon] ; Katsuya Nagatani [Japon] ; Taku Yoshio [Japon] ; Masahiro Iwamoto [Japon] ; Seiji Minota [Japon]Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease‐modifying antirheumatic drugs
002012 (2015) Shunsuke Mori ; Shigetoshi FujiyamaHepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations
003881 (2011) Matthew B. CarrollThe impact of biologic response modifiers on hepatitis B virus infection.
003980 (2011) Hideki Tsuboi [Japon] ; Akira Tsujii ; Akihide Nampei ; Harumasa Yoshihara ; Kiyoshi Kawano ; Eiji Takeuchi ; Kenrin ShiA patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis B.
004377 (????) Ioannis Papalopoulos [Grèce] ; Antonis Fanouriakis [Grèce] ; Nikolaos Kougkas [Grèce] ; Irini Flouri [Grèce] ; George Sourvinos [Grèce] ; George Bertsias [Grèce] ; Argyro Repa [Grèce] ; Nestor Avgoustidis [Grèce] ; Prodromos Sidiropoulos [Grèce]Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i -k "Hepatitis B" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i  \
                -Sk "Hepatitis B" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Hepatitis B
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021